Anti-CALCA / CGRP Reference Antibody (galcanezumab) is a recombinant monoclonal antibody used as a reference standard in biomedical research and assay development. It specifically targets and blocks calcitonin gene-related peptide (CGRP), a key molecule involved in migraine pathophysiology. By inhibiting CGRP activity, it serves as a tool to study the reduction in frequency and severity of migraine-like symptoms in preclinical models. This reference antibody mimics the mechanism of the therapeutic galcanezumab, which is administered via monthly subcutaneous injection for episodic and chronic migraine prevention in adults. It is also utilized in research exploring applications for cluster headaches and other CGRP-related pain disorders.